Daren Ure, Ph.D., CSO of Hepion Pharmaceuticals (NASDAQ:HEPA) will present an abstract on April 18 highlighting the company’s lead drug candidate, rencofilstat, at the American Association for Cancer Research annual meeting in Orlando.
The presentation is entitled, “Rencofilstat Exerts a Dominant Role in Synergistic Anti-PD1-Combination Effects in a Fatty Liver Model of Hepatocellular Carcinoma.”
A copy of the presentation materials will be accessible on the company’s website at https://hepionpharma.com/publications/.
